RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials